Beta

Serina therapeutics, inc.SER.US Overview

US StockHealthcare
(No presentation for SER)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

SER AI Insights

SER Overall Performance

SER AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SER Recent Performance

2.78%

Serina therapeutics, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

SER PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check SER's Trend

SER Key Information

SER Valuation Metrics

SER Profile

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

Price of SER

SER FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SER Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.92
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
186.61
PB Ratio
12.18
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-14755.38%
Revenue Growth (YoY)
132.14%
Profit Growth (YoY)
132.14%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.92
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
186.61
PB Ratio
12.18
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-14755.38%
Revenue Growth (YoY)
132.14%
Profit Growth (YoY)
132.14%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is SER's latest earnings report released?

    The most recent financial report for Serina therapeutics, inc. (SER) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SER's short-term business performance and financial health. For the latest updates on SER's earnings releases, visit this page regularly.

  • How is SER's revenue growth?

    In the latest financial report, Serina therapeutics, inc. (SER) announced revenue of 0, with a Year-Over-Year growth rate of 100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does SER have?

    At the end of the period, Serina therapeutics, inc. (SER) held Total Cash and Cash Equivalents of 3.06M, accounting for 0.44 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is SER's EPS continuing to grow?

    According to the past four quarterly reports, Serina therapeutics, inc. (SER)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.31. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SER?

    Serina therapeutics, inc. (SER)'s Free Cash Flow (FCF) for the period is -6.03M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 31.32% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of SER?

    The latest valuation data shows Serina therapeutics, inc. (SER) has a Price-To-Earnings (PE) ratio of -1.92 and a Price/Earnings-To-Growth (PEG) ratio of 0.05. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.